Lassa Fever Treatment Market Segmentation by Symptoms (Seizures, Tremor, Coma, Nausea, Vomiting, and Others); by Treatment {Medication (Ribavirin, and Others), Supportive Care, and Others} – Global Demand Analysis & Opportunity Outlook 2030
Buy Now Report ID: 3641 | Published Date: Feb 07, 2023
On the basis of geographical analysis, the global Lassa fever treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of increasing incidences of Lassa fever in the region. Lack of proper sanitation services in the region is also expected to significantly fuel the regional market growth. According to the statistics by the WHO, around 2 billion people do not have basic sanitation facilities, such as, toilets, especially in middle and low-income economies. Improving healthcare facilities, backed by increasing investment in the sector is further estimated to boost the market growth. According to the data by the World Bank, USD 520.89 were spent per capita on healthcare in the Middle East and North Africa region, in 2018.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the presence of major pharmaceutical companies in the region, along with high investment for research and development of new drugs.
Get more information on this report: Download Sample PDF
The global Lassa fever treatment market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global Lassa fever treatment market includes the following segments:
By Symptoms
By Treatment
Growth Drivers
Challenges
June, 2021: Novartis AG to collaborate with Hewlett Packard Enterprise to address global health challenges. Novartis is the leading pharmaceutical company distributing drugs over the years.
February 11, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Increasing investment to improve healthcare sector in underdeveloped economies is estimated to boost the market growth.
Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Ans: Lack of health awareness amongst people in the low-income countries is estimated to hamper the market growth.
Ans: The market in the North America region is estimated to provide more business opportunities owing to the presence of major pharmaceutical companies in the region.
Ans: The major players in the market are Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by symptoms, treatment, and by region.
Ans: The medications segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the presence of major pharmaceutical companies in the region, along with high investment for research and development of new drugs.
